.gif)
Zydus Cadila announced that new data of Saroglitazar will be presented at The Liver Meeting® being held at the John B. Hynes Veterans Memorial Convention Center, Boston
Kedrion Biopharma, and Kamada Ltd, two leading human-derived protein therapeutics companies, announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a human anti-rabies immunoglobulin (IgG) therapy. Rabies is a life-threatening condition that impacts approximately 40,000 people in the U.S. each year. At present, U.S. healthcare professionals have only two rabies IgG therapy options from which to select in preventing the onset of rabies in someone who may have been exposed to the deadly virus.
Immunovative Therapies, Ltd.(ITL) announced the start of a phase IIb study of CryoVax, a next generation immunotherapy cancer vaccine product, for patients with chemotherapy-refractory (third line) metastatic colorectal cancer (mCRC). The trial is being conducted by Banner MD Anderson Medical Center, in Phoenix, AZ, which is partnered with the world renowned University of Texas MD Anderson Cancer Center in Houston, TX, Recruitment in the trial is underway, and the first volunteers have received their initial vaccine doses. Enrollment is expected to be completed by the end of July 2017.
Amgen announced that the US Food and Drug Administration has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
Magnolia is a Pharmaceutical company having a blend of strong intellectual capital and dynamism.We deliver Active Pharmaceutical Ingredients (API) ,niche generics and flagship womencare products worldwide. It's a vibrant organization registering multi-fold growth year on year because of ambitious business efforts.
